On the World Diabetes Day, November 14, Diamyd Medical hosted an expert panel on the future of type 1 diabetes treatment.

The discussion explored:

• How close the field is to modifying the course of type 1 diabetes rather than only managing its symptoms
• The impact of preserving endogenous insulin production on long-term stability and quality of life
• The convergence of immune tolerance and precision medicine in therapies such as Diamyd Medical’s GAD65-based approach
• How insights from earlier GAD studies are shaping the ongoing Phase 3 trial, with results expected around March 2026

Panel participants

• Prof. Johnny Ludvigsson – pediatrician and T1D researcher, founder of Barndiabetesfonden and principal investigator in GAD/Diamyd^® trials.
• Joshua Vieth, Breakthrough T1D – leads research strategy at a global T1D non-profit funding disease-modifying trials, including prevention.
• Prof. Åke Lernmark – T1D researcher focused on genetics, HLA and autoantibodies, central to understanding risk and prevention of the disease.
• Ulf Hannelius, CEO, Diamyd Medical. Diamyd Medical is developing a GAD65-based precision therapy (Diamyd^®) to preserve the body’s own insulin production.

The webcast was produced by BioStock and moderated by Jonas Söderström.